Literature DB >> 9751756

The PEBP2betaMYH11 fusion created by Inv(16)(p13;q22) in myeloid leukemia impairs neutrophil maturation and contributes to granulocytic dysplasia.

S C Kogan1, E Lagasse, S Atwater, S C Bae, I Weissman, Y Ito, J M Bishop.   

Abstract

Chromosomal translocations involving the genes encoding the alpha and beta subunits of the Pebp2/Cbf transcription factor have been associated with human acute myeloid leukemia and the preleukemic condition, myelodysplasia. Inv(16)(p13;q22) fuses the gene encoding the beta subunit of Pebp2 to the MYH11 gene encoding a smooth muscle myosin heavy chain (Smmhc). To examine the effect of the inv(16)(p13;q22) on myelopoiesis, we used the hMRP8 promoter element to generate transgenic mice expressing the Pebp2betaSmmhc chimeric fusion protein in myeloid cells. Neutrophil maturation was impaired in PEBP2betaMYH11 transgenic mice. Although the transgenic mice had normal numbers of circulating neutrophils, their bone marrow contained increased numbers of immature neutrophilic cells, which exhibited abnormal characteristics. In addition, PEBP2betaMYH11 inhibited neutrophilic differentiation in colonies derived from hematopoietic progenitors. Coexpression of both PEBP2betaMYH11 and activated NRAS induced a more severe phenotype characterized by abnormal nuclear morphology indicative of granulocytic dysplasia. These results show that PEBP2betaMYH11 can impair neutrophil development and provide evidence that alterations of Pebp2 can contribute to the genesis of myelodysplasia.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9751756      PMCID: PMC21731          DOI: 10.1073/pnas.95.20.11863

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  38 in total

1.  Cytoplasmic sequestration of the polyomavirus enhancer binding protein 2 (PEBP2)/core binding factor alpha (CBFalpha) subunit by the leukemia-related PEBP2/CBFbeta-SMMHC fusion protein inhibits PEBP2/CBF-mediated transactivation.

Authors:  Y Kanno; T Kanno; C Sakakura; S C Bae; Y Ito
Journal:  Mol Cell Biol       Date:  1998-07       Impact factor: 4.272

2.  Acute myeloid leukemia with Inv (16) produces a chimeric transcription factor with a myosin heavy chain tail.

Authors:  P Liu; N Seidel; D Bodine; N Speck; S Tarlé; F S Collins
Journal:  Cold Spring Harb Symp Quant Biol       Date:  1994

3.  High frequency of t(12;21) in childhood B-lineage acute lymphoblastic leukemia.

Authors:  S P Romana; H Poirel; M Leconiat; M A Flexor; M Mauchauffé; P Jonveaux; E A Macintyre; R Berger; O A Bernard
Journal:  Blood       Date:  1995-12-01       Impact factor: 22.113

4.  Subcellular localization of the alpha and beta subunits of the acute myeloid leukemia-linked transcription factor PEBP2/CBF.

Authors:  J Lu; M Maruyama; M Satake; S C Bae; E Ogawa; H Kagoshima; K Shigesada; Y Ito
Journal:  Mol Cell Biol       Date:  1995-03       Impact factor: 4.272

5.  PEBP2/CBF, the murine homolog of the human myeloid AML1 and PEBP2 beta/CBF beta proto-oncoproteins, regulates the murine myeloperoxidase and neutrophil elastase genes in immature myeloid cells.

Authors:  I Nuchprayoon; S Meyers; L M Scott; J Suzow; S Hiebert; A D Friedman
Journal:  Mol Cell Biol       Date:  1994-08       Impact factor: 4.272

6.  Fusion of the TEL gene on 12p13 to the AML1 gene on 21q22 in acute lymphoblastic leukemia.

Authors:  T R Golub; G F Barker; S K Bohlander; S W Hiebert; D C Ward; P Bray-Ward; E Morgan; S C Raimondi; J D Rowley; D G Gilliland
Journal:  Proc Natl Acad Sci U S A       Date:  1995-05-23       Impact factor: 11.205

7.  Myristoylation and differential palmitoylation of the HCK protein-tyrosine kinases govern their attachment to membranes and association with caveolae.

Authors:  S M Robbins; N A Quintrell; J M Bishop
Journal:  Mol Cell Biol       Date:  1995-07       Impact factor: 4.272

8.  t(8;21) myelodysplasia, an early presentation of M2 AML.

Authors:  A S Taj; F M Ross; M Vickers; D N Choudhury; J F Harvey; J C Barber; C Barton; A G Smith
Journal:  Br J Haematol       Date:  1995-04       Impact factor: 6.998

9.  Correlation of cytogenetic results with immunophenotype, genotype, clinical features, and ras mutation in acute myeloid leukemia. A study of 235 Chinese patients in Taiwan.

Authors:  H F Tien; C H Wang; M T Lin; F Y Lee; M C Liu; S M Chuang; Y C Chen; M C Shen; K H Lin; D T Lin
Journal:  Cancer Genet Cytogenet       Date:  1995-10-01

10.  bcl-2 inhibits apoptosis of neutrophils but not their engulfment by macrophages.

Authors:  E Lagasse; I L Weissman
Journal:  J Exp Med       Date:  1994-03-01       Impact factor: 14.307

View more
  16 in total

1.  T-lymphoid, megakaryocyte, and granulocyte development are sensitive to decreases in CBFbeta dosage.

Authors:  Laleh Talebian; Zhe Li; Yalin Guo; Justin Gaudet; Maren E Speck; Daisuke Sugiyama; Prabhjot Kaur; Warren S Pear; Ivan Maillard; Nancy A Speck
Journal:  Blood       Date:  2006-08-29       Impact factor: 22.113

2.  Oncogenic NRAS, KRAS, and HRAS exhibit different leukemogenic potentials in mice.

Authors:  Chaitali Parikh; Ramesh Subrahmanyam; Ruibao Ren
Journal:  Cancer Res       Date:  2007-08-01       Impact factor: 12.701

Review 3.  Src family kinases and the MEK/ERK pathway in the regulation of myeloid differentiation and myeloid leukemogenesis.

Authors:  Daniel E Johnson
Journal:  Adv Enzyme Regul       Date:  2007-11-19

4.  AML1-ETO expression is directly involved in the development of acute myeloid leukemia in the presence of additional mutations.

Authors:  Y Yuan; L Zhou; T Miyamoto; H Iwasaki; N Harakawa; C J Hetherington; S A Burel; E Lagasse; I L Weissman; K Akashi; D E Zhang
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-28       Impact factor: 11.205

5.  Hematopoiesis and leukemogenesis in mice expressing oncogenic NrasG12D from the endogenous locus.

Authors:  Qing Li; Kevin M Haigis; Andrew McDaniel; Emily Harding-Theobald; Scott C Kogan; Keiko Akagi; Jasmine C Y Wong; Benjamin S Braun; Linda Wolff; Tyler Jacks; Kevin Shannon
Journal:  Blood       Date:  2010-12-16       Impact factor: 22.113

6.  Human AML1/MDS1/EVI1 fusion protein induces an acute myelogenous leukemia (AML) in mice: a model for human AML.

Authors:  G M Cuenco; G Nucifora; R Ren
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-15       Impact factor: 11.205

7.  Oncogenic NRAS rapidly and efficiently induces CMML- and AML-like diseases in mice.

Authors:  Chaitali Parikh; Ramesh Subrahmanyam; Ruibao Ren
Journal:  Blood       Date:  2006-06-08       Impact factor: 22.113

8.  RAS oncogene suppression induces apoptosis followed by more differentiated and less myelosuppressive disease upon relapse of acute myeloid leukemia.

Authors:  Won-Il Kim; Ilze Matise; Miechaleen D Diers; David A Largaespada
Journal:  Blood       Date:  2008-10-24       Impact factor: 22.113

Review 9.  Engineering mouse models with myelodysplastic syndrome human candidate genes; how relevant are they?

Authors:  Stephanie Beurlet; Christine Chomienne; Rose Ann Padua
Journal:  Haematologica       Date:  2012-10-12       Impact factor: 9.941

10.  FLT3-ITD cooperates with inv(16) to promote progression to acute myeloid leukemia.

Authors:  Hyung-Gyoon Kim; Kyoko Kojima; C Scott Swindle; Claudiu V Cotta; Yongliang Huo; Vishnu Reddy; Christopher A Klug
Journal:  Blood       Date:  2007-10-29       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.